Tests brain stimulation with movement therapy to reduce fatigue in multiple sclerosis
Tests weak electrical brain stimulation with motor therapy in adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Evaluation of the Efficacy of Transcranial Direct Current Stimulation in Reducing Fatigue and Improving Quality of Life in Patients With Multiple Sclerosis: A Randomized Clinical Trial
Key facts
- Where
- Madrid, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple sclerosis who have felt fatigue for the last 6 months and have had no relapse in the last 2 months.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Multiple sclerosis defined by the McDonald criteria (2017 revised version), with no relapse in the last 2 months.
- Earlier treatment
- Must have had stable drug treatment in the last month. Cannot be on, or need, immunosuppressive MS treatment with Ocrelizumab, Rituximab, Lemtrada or Mavenclad one week before or during the trial.
- Biomarker or test result
- Fatigue in the last 6 months, with a Fatigue Severity Scale (FSS) score above 4.
Main reasons for not taking part
- No stable drug treatment in the last month
- Contraindications to tDCS, such as pacemaker, defibrillator, brain stimulator, implanted metal in the skull, skull fracture, epilepsy, pregnancy
- Immunosuppressive MS treatment with Ocrelizumab, Rituximab, Lemtrada or Mavenclad around the time of tDCS
- Memory or thinking problems that make it hard to understand the scales
- Side effects from tDCS, or unable to complete the third cycle and the V3 assessment
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06873464, who can take part
Where in Spain
- Fundación Esclerosis Multiple MadridMadrid, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European University of Madrid
- Trial code
- NCT06873464
- Record updated
- 12 March 2025
- Original description
The goal of this clinical trial is to evaluate whether the application of three 2-week cycles of tDCS combined with motor therapy is more effective in reducing fatigue in adult patients with multiple sclerosis, compared to the application of two cycles of the same treatment. The main questions aim to answer:Read full original descriptionShow less
Evaluation of the Efficacy of Transcranial Direct Current Stimulation in Reducing Fatigue and Improving Quality of Life in Patients With Multiple Sclerosis: A Randomized Clinical Trial
The goal of this clinical trial is to evaluate whether the application of three 2-week cycles of tDCS combined with motor therapy is more effective in reducing fatigue in adult patients with multiple sclerosis, compared to the application of two cycles of the same treatment. The main questions aim to answer:
* Is the application of three 2-week cycles of tDCS combined with motor therapy (experimental group) more effective for the recovery of fatigue in adult patients with multiple sclerosis compared to the application of two cycles of the same treatment (control group)? * Is tDCS combined with motor therapy effective in improving fatigue in adult patients with multiple sclerosis in both study arms, i.e., in the pre-post assessment of the experimental group and the pre-post assessment of the control group? Researchers will compare the application of three 2-week cycles of tDCS combined with motor therapy (experimental group) to the application of two cycles of the same treatment (control group) to see if the experimental group shows greater recovery of fatigue in adult patients with multiple sclerosis.
Participants will:
* Visit the clinic for two weeks to be evaluated (baseline measurement and first post-treatment assessment) and receive the first cycle of treatment from Monday to Friday. * Have a washout period of one month between the first and the second cycle. * Visit the clinic for two weeks to receive the second cycle of treatment and be evaluated (second post-treatment assessment). * Only participants in the experimental group will have another washout period of one month and visit the clinic to receive a third cycle of treatment and to be evaluated (third post-treatment assessment). * Only participants in the control group will visit the clinic one and a half months after completing their second cycle to be measured as a follow-up.
Inclusion: Patients with multiple sclerosis defined according to the McDonald criteria (2017 revised version); Age between 18 and 75 years; No relapse in the last 2 months; Fatigue experienced in the last 6 months, according to the Fatigue Severity Scale (FSS > 4).
Exclusion: Patients who are undergoing or need to undergo immunosuppressive treatment for MS with Ocrelizumab, Rituximab, Lemtrada, or Mavenclad one week before or during the application of tDCS; Patients with contraindications to the use of tDCS, such as: defibrillator, pacemaker, brain stimulator, implanted intracranial metals, skull fractures or fissures, damaged skin or recent scars, epilepsy, pregnancy; Patients who have not had stable pharmacological treatment in the last month; Patients with cognitive difficulties that prevent them from understanding the applied scales; Patients who experience adverse effects from tDCS treatment; Inability to remain in the study and complete the third cycle and/or the V3 assessment.